Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
1(10%)
Results Posted
43%(3 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_2
5
50%
Ph phase_1
5
50%

Phase Distribution

5

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
5(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(7)
Terminated(2)

Detailed Status

Completed7
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
77.8%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (50.0%)
Phase 25 (50.0%)

Trials by Status

active_not_recruiting110%
terminated220%
completed770%

Recent Activity

1 active trials
Showing 5 of 10
active_not_recruitingphase_2

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

NCT02299999
completedphase_2

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

NCT02117167
completedphase_2

Phase I/II Trial of Antagonism of HER in GI Cancer

NCT01862003
completedphase_1

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

NCT00900627
terminatedphase_2

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

NCT01579578
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02299999Phase 2

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active Not Recruiting
NCT02117167Phase 2

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Completed
NCT01862003Phase 2

Phase I/II Trial of Antagonism of HER in GI Cancer

Completed
NCT00900627Phase 1

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

Completed
NCT01579578Phase 2

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

Terminated
NCT01151215Phase 2

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

Terminated
NCT01003158Phase 1

Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.

Completed
NCT00637039Phase 1

Study of AZD8931 in Patients With Advanced Solid Malignancies

Completed
NCT01330758Phase 1

A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females

Completed
NCT00879346Phase 1

A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10